Home

Nektar Therapeutics - Common Stock (NKTR)

0.8972
+0.0170 (1.93%)

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapies to treat a variety of diseases, including cancer and autoimmune disorders

The company specializes in applying its proprietary drug delivery technology to enhance the efficacy and safety of existing therapies, as well as creating new treatments from the ground up. Nektar collaborates with other pharmaceutical organizations to advance its research pipeline and aims to address unmet medical needs by delivering transformative medicines that improve patients' lives.

SummaryNewsPress ReleasesChartHistoricalFAQ
Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws.
By Glancy Prongay & Murray LLP · Via Business Wire · February 1, 2023
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.
By Bristol Myers Squibb · Via Business Wire · March 14, 2022
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent […]
Via FinancialNewsMedia · December 10, 2021